Sodium-glucose co-transporter-2 inhibitors: A paradigm shift in treatment for type 2 diabetes

被引：1

作者：

Matthews, David R. ^{[1
]}

机构：

[1] Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England

来源：

DIABETES OBESITY & METABOLISM | 2024年 / 26卷

关键词：

canagliflozin; cardiovascular disease; heart failure; SGLT2; inhibitor; CARDIOVASCULAR OUTCOMES;

D O I：

10.1111/dom.15963

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3 / 4

页数：2

共 15 条

[1]

[Anonymous], 1993, NEW ENGL J MED, V329, P977, DOI [10.1056/NEJM199309303291401, DOI 10.1056/NEJM199309303291401]

[2] Chronic kidney disease in type 2 diabetes: The size of the problem, addressing residual renal risk and what we have learned from the CREDENCE trial [J].

Chaudhry, Khuram ;

Karalliedde, Janaka .

DIABETES OBESITY & METABOLISM, 2024, 26 :25-34

[3] An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes [J].

Chen, Angela X. ;

Fletcher, Robert ;

Neuen, Brendon L. ;

Neal, Bruce ;

Arnott, Clare .

DIABETES OBESITY & METABOLISM, 2024, 26 :5-13

[4] Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024 [J].

ElSayed, Nuha A. ;

Aleppo, Grazia ;

Bannuru, Raveendhara R. ;

Bruemmer, Dennis ;

Collins, Billy S. ;

Ekhlaspour, Laya ;

Gaglia, Jason L. ;

Hilliard, Marisa E. ;

Johnson, Eric L. ;

Khunti, Kamlesh ;

Lingvay, Ildiko ;

Matfin, Glenn ;

McCoy, Rozalina G. ;

Perry, Mary Lou ;

Pilla, Scott J. ;

Polsky, Sarit ;

Prahalad, Priya ;

Pratley, Richard E. ;

Segal, Alissa R. ;

Seley, Jane Jeffrie ;

Stanton, Robert C. ;

Gabbay, Robert A. ;

Beverly, Elizabeth A. ;

Cusi, Kenneth ;

Darville, Audrey ;

Das, Sandeep R. ;

Fleming, Talya K. ;

Gaglia, Jason L. ;

Galindo, Rodolfo J. ;

Gibbons, Christopher H. ;

Giurini, John M. ;

Hassanein, Mohamed ;

Kosiborod, Mikhail N. ;

Kushner, Robert F. ;

Murdock, Lisa ;

Napoli, Nicola ;

Selvin, Elizabeth ;

Silva, Paolo S. ;

Verduzco-Gutierrez, Monica ;

Woodward, Crystal C. ;

Younossi, Zobair M. ;

Pekas, Elizabeth J. ;

Yacoubian, Alexandra M. .

DIABETES CARE, 2024, 47 :S158-S178

[5] The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD New features and the 'Ten Commandments' of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen [J].

Grant, Peter J. ;

Cosentino, Francesco .

EUROPEAN HEART JOURNAL, 2019, 40 (39) :3215-3217

[6] Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes [J].

Hayward, Rodney A. ;

Reaven, Peter D. ;

Wiitala, Wyndy L. ;

Bahn, Gideon D. ;

Reda, Domenic J. ;

Ge, Ling ;

McCarren, Madeline ;

Duckworth, William C. ;

Emanuele, Nicholas V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (23) :2197-2206

[7]

MARSHALL BJ, 1988, LANCET, V2, P1437

[8] 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC) [J].

Marx, Nikolaus ;

Federici, Massimo ;

Schuett, Katharina ;

Mueller-Wieland, Dirk ;

Ajjan, Ramzi A. ;

Antunes, Manuel J. ;

Christodorescu, Ruxandra M. ;

Crawford, Carolyn ;

Di Angelantonio, Emanuele ;

Eliasson, Bjorn ;

Espinola-Klein, Christine ;

Fauchier, Laurent ;

Halle, Martin ;

Herrington, William G. ;

Kautzky-Willer, Alexandra ;

Lambrinou, Ekaterini ;

Lesiak, Maciej ;

Lettino, Maddalena ;

Mcguire, Darren K. ;

Mullens, Wilfried ;

Rocca, Bianca ;

Sattar, Naveed .

EUROPEAN HEART JOURNAL, 2023, 44 (39) :4043-4140

[9] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes [J].

Neal, Bruce ;

Perkovic, Vlado ;

Mahaffey, Kenneth W. ;

de Zeeuw, Dick ;

Fulcher, Greg ;

Erondu, Ngozi ;

Shaw, Wayne ;

Law, Gordon ;

Desai, Mehul ;

Matthews, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) :644-657

[10] Key results from observational studies and real-world evidence of sodium-glucose cotransporter-2 inhibitor effectiveness and safety in reducing cardio-renal risk [J].

Nystroem, Thomas .

DIABETES OBESITY & METABOLISM, 2024, 26 :35-57

← 1 2 →